[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2009010660A3 - Indazoles substitues, leur preparation et leur utilisation en therapeutique - Google Patents

Indazoles substitues, leur preparation et leur utilisation en therapeutique Download PDF

Info

Publication number
WO2009010660A3
WO2009010660A3 PCT/FR2008/000843 FR2008000843W WO2009010660A3 WO 2009010660 A3 WO2009010660 A3 WO 2009010660A3 FR 2008000843 W FR2008000843 W FR 2008000843W WO 2009010660 A3 WO2009010660 A3 WO 2009010660A3
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
group
heterocycloalkyl
alkenyl
aryl
Prior art date
Application number
PCT/FR2008/000843
Other languages
English (en)
Other versions
WO2009010660A2 (fr
Inventor
Michel Aletru
Dominique Damour
Catherine Monseau
Patrick Mougenot
Claudie Namane
Frederico Nardi
Patrick Nemecek
Christophe Philippo
Original Assignee
Sanofi Aventis
Michel Aletru
Dominique Damour
Catherine Monseau
Patrick Mougenot
Claudie Namane
Frederico Nardi
Patrick Nemecek
Christophe Philippo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39126183&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2009010660(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis, Michel Aletru, Dominique Damour, Catherine Monseau, Patrick Mougenot, Claudie Namane, Frederico Nardi, Patrick Nemecek, Christophe Philippo filed Critical Sanofi Aventis
Priority to EP08826411A priority Critical patent/EP2170865A2/fr
Priority to JP2010512736A priority patent/JP2010530402A/ja
Publication of WO2009010660A2 publication Critical patent/WO2009010660A2/fr
Publication of WO2009010660A3 publication Critical patent/WO2009010660A3/fr
Priority to US12/636,357 priority patent/US20100298377A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention est relative à des composés de formule (I) dans laquelle : E désigne un groupement : (i) de formule -NT-CO-O- ou -NT-CX-NT'- dans laquelle X désigne =O ou =S et T et T', pouvant être identiques ou différents, sont choisis indépendamment parmi H ou un groupe alkyle ou (ii) formant un cycle à 5 ou 6 chaînons qui est rattaché en position 5 ou 6 au noyau indazole par -NT- ou par l'atome d'azote N1; R1 représente un ou plusieurs substituant(s), choisis indépendamment l'un de l'autre lorsqu'il y en a plusieurs, pouvant être : un atome d'halogène, un groupe alkyle, alkényle, alkynyle, halogénoalkyle, halogénoalcoxy, aryle, hétéroaryle, hétérocycloalkyle, cycloalkyle, CN, NRR', OR, NO2, COOR, CONRR', NRCOR'; R2 représente un atome d'hydrogène, un groupe alkyle, alkényle ou alkynyle; R3 représente un ou plusieurs substituant(s), choisis indépendamment l'un de l'autre lorsqu'il y en a plusieurs et pouvant être : un atome d'halogène, un groupe alkyle, alkényle, alkynyle, halogénoalcoxy, aryle, hétéroaryle, cycloalkyle, hétérocycloalkyle, CN, NRR', CF3, OR, NO2, COOR, CONRR', NRCOR'; R4 désigne un atome d'hydrogène ou d'halogène, un groupe alkyle, alkényle, alkynyle, aryle, hétéroaryle, hétérocycloalkyle, -NR-CO-R', COOR, NRR', CHO, CONR(OR'); R et R', pouvant être identiques ou différents, désignent indépendamment l'un de l'autre : un atome d'hydrogène, un groupe alkyle, aryle, hétérocycloalkyle, cycloalkyle ou hétéroaryle; n1 représente un nombre entier allant de 0 à 5 et n3 un nombre entier allant de 0 à 3.
PCT/FR2008/000843 2007-06-21 2008-06-18 Indazoles substitues, leur preparation et leur utilisation en therapeutique WO2009010660A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP08826411A EP2170865A2 (fr) 2007-06-21 2008-06-18 Indazoles substitues, leur preparation et leur utilisation en therapeutique
JP2010512736A JP2010530402A (ja) 2007-06-21 2008-06-18 置換インダゾール類、それらの調製および治療におけるその使用
US12/636,357 US20100298377A1 (en) 2007-06-21 2009-12-11 Novel substituted indazoles, the preparation thereof and use of same in therapeutics

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0704422A FR2917735B1 (fr) 2007-06-21 2007-06-21 Nouveaux indazoles substitutes, leur preparation et leur utilisation en therapeutique
FR0704422 2007-06-21

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/636,357 Continuation US20100298377A1 (en) 2007-06-21 2009-12-11 Novel substituted indazoles, the preparation thereof and use of same in therapeutics

Publications (2)

Publication Number Publication Date
WO2009010660A2 WO2009010660A2 (fr) 2009-01-22
WO2009010660A3 true WO2009010660A3 (fr) 2009-04-16

Family

ID=39126183

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2008/000843 WO2009010660A2 (fr) 2007-06-21 2008-06-18 Indazoles substitues, leur preparation et leur utilisation en therapeutique

Country Status (11)

Country Link
US (1) US20100298377A1 (fr)
EP (1) EP2170865A2 (fr)
JP (1) JP2010530402A (fr)
AR (1) AR067051A1 (fr)
CL (1) CL2008001815A1 (fr)
FR (1) FR2917735B1 (fr)
PA (1) PA8785301A1 (fr)
PE (1) PE20090369A1 (fr)
TW (1) TW200909425A (fr)
UY (1) UY31166A1 (fr)
WO (1) WO2009010660A2 (fr)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8252812B2 (en) 2009-08-10 2012-08-28 Samumed, Llc Indazole inhibitors of the WNT signal pathway and therapeutic uses thereof
EP2515655B1 (fr) 2009-12-21 2015-08-05 Samumed, LLC 1h-pyrazolo[3,4-beta]pyridines et leurs utilisations thérapeutiques
JP2014509660A (ja) * 2011-04-01 2014-04-21 ユニバーシティ・オブ・ユタ・リサーチ・ファウンデイション ＰＤＫ１キナーゼの阻害剤としての置換３−（１Ｈ−ベンゾ｛ｄ｝イミダゾール−２−イル）−１Ｈ−インダゾール類似体
PL2755483T3 (pl) 2011-09-14 2019-06-28 Samumed, Llc Indazolo-3-karboksyamidy i ich zastosowanie jako inhibitorów szlaków sygnalizacji WNT/B-kateniny
KR20130073822A (ko) 2011-12-23 2013-07-03 가부시키가이샤 한도오따이 에네루기 켄큐쇼 이온 액체, 비수 전해질 및 축전 장치
PH12017500997A1 (en) 2012-04-04 2018-02-19 Samumed Llc Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
MY173049A (en) 2012-05-04 2019-12-20 Samumed Llc 1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
WO2014110086A2 (fr) 2013-01-08 2014-07-17 Samumed, Llc Inhibiteurs de 3-(benzoimidazol-2-yl)-indazole de la voie de signalisation par wnt et leurs utilisations thérapeutiques
CA2905242C (fr) 2013-03-15 2016-11-29 Pfizer Inc. Composes indoliques activant l'ampk
WO2016040182A1 (fr) 2014-09-08 2016-03-17 Samumed, Llc 2-(1h-indazol-3-yl)-1h-imidazo[4,5-c]pyridine et ses utilisations thérapeutiques
WO2016040188A1 (fr) 2014-09-08 2016-03-17 Samumed, Llc 3-3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine et ses utilisations thérapeutiques
WO2016040193A1 (fr) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine et ses utilisations thérapeutiques
WO2016040190A1 (fr) 2014-09-08 2016-03-17 Samumed, Llc 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine et ses utilisations thérapeutiques
WO2016040185A1 (fr) 2014-09-08 2016-03-17 Samumed, Llc 2-1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine et ses utilisations thérapeutiques
WO2016040184A1 (fr) 2014-09-08 2016-03-17 Samumed, Llc 3-3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine et ses utilisations thérapeutiques
WO2016040181A1 (fr) 2014-09-08 2016-03-17 Samumed, Llc 3-1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine et ses utilisations thérapeutiques
WO2016040180A1 (fr) 2014-09-08 2016-03-17 Samumed, Llc 3-1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine et ses utilisations thérapeutiques
JO3705B1 (ar) 2014-11-26 2021-01-31 Bayer Pharma AG إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية
WO2017024004A1 (fr) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines et leurs utilisations thérapeutiques
US10166218B2 (en) 2015-08-03 2019-01-01 Samumed, Llc 3-(1H-indol-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
WO2017023986A1 (fr) 2015-08-03 2017-02-09 Samumed, Llc 3-(1h-indol-2-yl)-1h-indazoles et leurs utilisations thérapeutiques
US10519169B2 (en) 2015-08-03 2019-12-31 Samumed, Llc 3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
WO2017024010A1 (fr) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-indazoles et leurs utilisations thérapeutiques
US10188634B2 (en) 2015-08-03 2019-01-29 Samumed, Llc 3-(3H-imidazo[4,5-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
WO2017023984A1 (fr) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines et leurs utilisations thérapeutiques
WO2017023972A1 (fr) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines et leurs utilisations thérapeutiques
WO2017023987A1 (fr) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridines et leurs utilisations thérapeutiques
WO2017023989A1 (fr) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[4,3-b]pyridines et leurs utilisations thérapeutiques
US10226453B2 (en) 2015-08-03 2019-03-12 Samumed, Llc 3-(1H-indol-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
WO2017024015A1 (fr) 2015-08-03 2017-02-09 Samumed, Llc. 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines et leurs utilisations thérapeutiques
WO2017024021A1 (fr) 2015-08-03 2017-02-09 Samumed, Llc 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles et leurs utilisations thérapeutiques
US10285982B2 (en) 2015-08-03 2019-05-14 Samumed, Llc 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
WO2017023996A1 (fr) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridines et leurs utilisations thérapeutiques
US10383861B2 (en) 2015-08-03 2019-08-20 Sammumed, LLC 3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
US10231956B2 (en) 2015-08-03 2019-03-19 Samumed, Llc 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
KR20180080262A (ko) 2015-11-06 2018-07-11 사뮤메드, 엘엘씨 골관절염의 치료
PL3464285T3 (pl) 2016-06-01 2023-02-06 Biosplice Therapeutics, Inc. Sposób wytwarzania n-(5-(3-(7-(3-fluorofenylo)-3h-imidazo[4,5-c]pirydyn-2-ylo)-1h-indazol-5-ilo)pirydyn-3-ylo)-3-metylobutanoamidu
WO2018075858A1 (fr) 2016-10-21 2018-04-26 Samumed, Llc PROCÉDÉS D'UTILISATION D'INDAZOLE-3-CARBOXAMIDES ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE LA VOIE DE SIGNALISATION WNT/β-CATÉNINE
JP2019533702A (ja) 2016-11-07 2019-11-21 サミュメッド リミテッド ライアビリティ カンパニー 単回用量の調整済み注射用製剤
GB201714745D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714734D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714736D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714740D0 (en) * 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201903827D0 (en) * 2019-03-20 2019-05-01 Atrogi Ab New compounds and methods
GB201903832D0 (en) * 2019-03-20 2019-05-01 Atrogi Ab New compounds and methods

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002010137A2 (fr) * 2000-07-31 2002-02-07 Signal Pharmaceuticals, Inc. Derives d'indazole utilises comme inhibiteurs de jnk et compositions et methodes associees a ceux-ci
FR2836914A1 (fr) * 2002-03-11 2003-09-12 Aventis Pharma Sa Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
WO2005037792A1 (fr) * 2003-10-17 2005-04-28 Sanofi-Aventis Derives de n-``phenyl(piperidin-2-yl)methyl !benzamide, leur preparation et leur application en therapeutique
WO2006135383A2 (fr) * 2004-08-04 2006-12-21 Myriad Genetics, Inc. Indazoles

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2690440B1 (fr) * 1992-04-27 1995-05-19 Rhone Poulenc Agrochimie Arylpyrazoles fongicides.
FR2823209B1 (fr) * 2001-04-04 2003-12-12 Fournier Lab Sa Nouvelles thiohydantoines et leur utilisation en therapeutique
FR2838739B1 (fr) * 2002-04-19 2004-05-28 Sanofi Synthelabo Derives de n-[phenyl(piperidin-2-yl)methyl)benzamide, leur preparation et leur application en therapeutique
DE102005059479A1 (de) 2005-12-13 2007-06-14 Merck Patent Gmbh Hydroxychinolinderivate
CA2703497A1 (fr) 2007-11-06 2009-05-14 N.V. Organon Procede de diminution du taux d'hormone chez les etres humains

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002010137A2 (fr) * 2000-07-31 2002-02-07 Signal Pharmaceuticals, Inc. Derives d'indazole utilises comme inhibiteurs de jnk et compositions et methodes associees a ceux-ci
FR2836914A1 (fr) * 2002-03-11 2003-09-12 Aventis Pharma Sa Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
WO2003078402A1 (fr) * 2002-03-11 2003-09-25 Aventis Pharma S.A. Indazoles substitues avec une activite anticancereuse
WO2005037792A1 (fr) * 2003-10-17 2005-04-28 Sanofi-Aventis Derives de n-``phenyl(piperidin-2-yl)methyl !benzamide, leur preparation et leur application en therapeutique
WO2006135383A2 (fr) * 2004-08-04 2006-12-21 Myriad Genetics, Inc. Indazoles

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DUMAS J: "PROTEIN KINASE INHIBITORS FROM THE UREA CLASS", CURRENT OPINION IN DRUG DISCOVERY AND DEVELOPMENT, CURRENT DRUGS, LONDON, GB, vol. 5, no. 5, 2002, pages 718 - 727, XP009011493, ISSN: 1367-6733 *

Also Published As

Publication number Publication date
EP2170865A2 (fr) 2010-04-07
UY31166A1 (es) 2009-01-30
FR2917735B1 (fr) 2009-09-04
AR067051A1 (es) 2009-09-30
PA8785301A1 (es) 2009-01-23
FR2917735A1 (fr) 2008-12-26
TW200909425A (en) 2009-03-01
CL2008001815A1 (es) 2009-09-11
US20100298377A1 (en) 2010-11-25
WO2009010660A2 (fr) 2009-01-22
JP2010530402A (ja) 2010-09-09
PE20090369A1 (es) 2009-04-30

Similar Documents

Publication Publication Date Title
WO2009010660A3 (fr) Indazoles substitues, leur preparation et leur utilisation en therapeutique
EA200970656A1 (ru) Вич-ингибирующие 5,6-замещенные пиримидины
NO20085140L (no) Nye indazolderivater som har spiro ringstruktur i sidekjede
ATE556058T1 (de) 1-(2h)-isochinolonderivat
MX2009008509A (es) Compuesto de anillo puenteado-aza.
RS50537B (sr) Derivati benzimidazola i njihovo korišćenje kao antagonista receptora a ii
JP2008530099A5 (fr)
ATE553106T1 (de) Heteroarylpyrrolopyridinone als kinaseinhibitoren
NO20074641L (no) 1-Acetic Acid-Indole Derivatives with PGD2 Antagonist Activity
WO2009156861A3 (fr) Dérivés de pyrimidone substitués
RS54708B1 (en) ARYLETINYL DERIVATIVES
JP2010504286A5 (fr)
MX362940B (es) Nuevo derivado de nicotinamida o la sal del mismo.
HRP20130653T1 (en) Pyrrole compounds
WO2008108378A3 (fr) Dérivé bicyclique d'oxomorpholine
NO20092770L (no) Nye aminopyrimidinderivater som PLK1-inhibitorer
NZ603896A (en) 3-amino-5,6-dihydro-1h-pyrazin-2-one derivatives useful for the treatement of alzheimer's disease and other forms of dementia
RS51674B (en) PIPERIDIN-4-IL-PIRIDAZIN-3-ILAMINE DERIVATIVES AS A FAST DISSOCATING DOPAMIN 2 RECEIVER ANTAGONISTS
WO2008107502A8 (fr) Composition destinée à traiter des maladies infectieuses
NO20074311L (no) Kinazolinderivat med tyrosinkinase-inhiberendeaktivitet
WO2009095792A3 (fr) Dérivés d'hétéroarylamide diazépinopyrimidone substitués
DK2868660T3 (da) Anti-tumoreffekt-potentiator omfattende en imidazooxazin-forbindelse
RS51557B (en) 4H-1,2,4-TRIAZIN-5-ONE DERIVATIVES, THEIR PRODUCTION AND THEIR USE AS ALFA 7 NICOTINE ACETYLHOLINE RECEPTORS
TNSN07439A1 (en) Derivatives of,4,5 - diarylpyrrole, preparation method thereof and use of same in therapeutics
AR056418A1 (es) Derivados de bencimidazol como 5-ht6, 5-ht2a, metodo para la obtencion del compuesto y el uso para la fabricacion de un mediicamento

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08826411

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2008826411

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2010512736

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE